Key result
A novel VO2peak prediction model tailored for endurance athletes was developed using age, sex, and height, as standard general population equations perform poorly in this cohort.
Why the study?
Does a novel VO2peak prediction model provide more accurate reference values for endurance athletes compared to general population equations?
Does a novel VO2peak prediction model provide more accurate reference values for endurance athletes compared to general population equations?
Answers are grounded in this paper and cite their sources.
Standard CPET reference values underestimate functional capacity in endurance athletes, necessitating the use of athlete-specific VO2peak prediction models for accurate cardiovascular risk stratification.
This editorial refers to ‘Normative cardiopulmonary exercise data for endurance athletes: the Cardiopulmonary Health and Endurance Exercise Registry (CHEER)’, by B.J. Petek et al., pp. 536--544. The rapidly developing field of sports cardiology is facing many challenges. One of these is to identify cardiovascular risk in an increasing number of highly active people engaging in competitive sports at a formally non-professional level, who present for cardiac check-ups. As such, sports cardiologists need reliable clinical tools to define what is normal and what is pathological in this particular population. In an area where most efforts have been put in defining the ‘athlete’s heart’ based upon reference standards for electrocardiography and non-invasive imaging, cardiopulmonary exercise testing (CPET) represents the ‘Cinderella’ of diagnostic tests in this setting. For a long time, CPET remained the prerogative of the evaluation of patients with heart failure.1 Accordingly, reference values for this population were developed only in comparison to healthy, sedentary controls. Up to now, only few data are available about how to interpret CPET in a real-world population of non-professional endurance athletes (EAs).2,3 However, EA represent a large and important study-population currently under-investigated, heterogeneous in terms of age and gender and including highly active people engaging in competitive sports, where athletic excellence is warranted and achieved.4 As individualized medicine represents the future of modern clinical practice, reference values to objectively quantify exercise capacity and other important data gained by CPET provide the comparative basis to allow a reliable risk-stratification. In this issue of EJPC, Petek et al. aim to fill this gap and provide a key paper on how to interpret CPET parameters in EA.5 In this context, special attention should be dedicated to the baseline characteristics of the cohort analysed. The mean age was 42 ± 15 years old, thus well representing the large and relevant population of high-level, yet amateurs, athletes. Although the majority of the athletes (65%) presented for clinical evaluation of symptoms, only those who had no explanatory heart or lung pathology were included in the final cohort, in order to exclude cardiovascular or pulmonary conditions that could adversely impact CPET results. Another 19% of athletes underwent CPET to investigate exercise physiology due to known cardiovascular risk factors: 14% were hypertensive (10% under medical treatment) and 14% had hyperlipidaemia (7% on therapy with statin). Athletes with a diagnosis of paroxysmal atrial fibrillation were included, too. Finally, 16% of athletes presented for CPET to follow-up findings on other cardiac testing or exam, such as electrocardiogram alterations or a heart murmur. As such, Petek et al. adequately identified a real-world, reference cohort, to allow an accurate cardiovascular risk stratification in EA. Although higher levels of physical activity are associated with a lower all-cause mortality, previous studies found athletes to have up to a 2.6-times higher risk of sudden cardiac death due to premature coronary artery disease, which is mostly silent until plaque rupture.6 The interpretation of CPET parameters based on the same reference values as for the normal population may be misleading due to the baseline functional status being significantly above the normal limits. Peak oxygen consumption (VO2peak) represents a gold-standard to assess functional capacity and reflects the coupling of the cardiovascular and respiratory system with skeletal muscles as an ‘integrative exercise response’. Consequently, in EA even a reduced VO2peak in the setting of a subjectively reduced performance might still be ‘physiologic’ or even above the normal reference values for the general population. Accordingly, in the cohort presented by Petek et al. EA presented with a constantly higher VO2peak than predicted based on general population, and this trend was maintained across all age ranges. In the presented study, the authors move even further and analyse the performance of the commonly used equations for VO2peak calculation in EA. VO2peak, i.e. the muscular peak oxygen consumption, is a derived measure based upon standard parameters such as age, gender, and weight (Table 1). The model for VO2peak prediction presented in this issue was developed based on multivariable analyses and included age, sex, and height. Up to now, clinically used equations for VO2peak have been developed based on small general population cohorts of mostly sedentary subjects and, obviously, perform poorly among EA. Previously developed VO2peak equations for athletes were analysed in this cohort, however, they overestimated the VO2peak in younger athletes and predicted a steeper decline with age. These discrepancies are likely due to relevant differences in the baseline characteristics or in the sample size of the population analysed. To correct for these possible biases, Petek et al. stratified CPET data by age—including a wide age range from 18 to 74 years—and gender, in order to generate a novel model for VO2peak prediction specifically tailored for EA, both on the treadmill and on the cycle ergometer. These equations were validated in a small, yet comparable, external validation cohort. Finally, the identification of reference CPET values is challenging both in healthy subjects and in athletes due to heterogeneity of protocol, equipment, study methodology, population selection, and parameters utilized. The cohort presented by Petek et al. consists of 272 EA, which were thoughtfully selected starting from a population of 1497 athletes. In comparison, a previous study.7 included only 56 cyclists, while two other meta-analyses present data from very heterogeneous studies, thus, data which cannot reliably serve as reference values.2,3 Although the proposed new VO2peak equation has been validated in an external cohort, bigger validation cohorts covering the whole span of age ranges and possibly focusing on older ages are needed. Furthermore, these equations should be tested in athletes who perform a CPET in order to improve their athletic performance and who present asymptomatic in order to better exclude occult cardiovascular pathologies. Missing data also exist on the field of racial differences, as acknowledged by the authors. Although further clinical studies are still needed, the brilliant work of Petek et al. set an important milestone in defining the reference values for CPET interpretation and will translate into a prompt application into clinical practice. Conflict of interest: none declared. The opinions expressed in this article are not necessarily those of the Editors of the European Journal of Preventive Cardiology or of the European Society of Cardiology.
No takes yet. Share an insight, caveat, or question.
Rossi et al. (2021) conducted an editorial in Endurance athletes (n=272). Cardiopulmonary exercise testing (CPET) vs. General population reference values was evaluated on VO2peak prediction. A novel VO2peak prediction model tailored for endurance athletes was developed using age, sex, and height, as standard general population equations perform poorly in this cohort.
Synapse has enriched 10 related papers. Consider them for comparative context: